ArticleScientific reports2020
Engineering bioactive surfaces on nanoparticles and their biological interactions.
Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 47 citations in OpenAlex.
- Bioresponsive engineered nanoparticles for immunomodulation.BMC medicine · 2025Review
- Evaluating Biocompatibility: From Classical Techniques to State-of-the-Art Functional Proteomics.Nanomaterials (Basel, Switzerland) · 2025Review
- Nano-based drug delivery systems for active ingredients from traditional Chinese medicine: Harnessing the power of nanotechnology.Frontiers in pharmacology · 2024Review
- Silver/Graphene Oxide Nanostructured Coatings for Modulating the Microbial Susceptibility of Fixation Devices Used in Knee Surgery.International journal of molecular sciences · 2023Article
- Silver-Gold Alloy Nanoparticles (AgAu NPs): Photochemical Synthesis of Novel Biocompatible, Bimetallic Alloy Nanoparticles and Study of Their In Vitro Peroxidase Nanozyme Activity.Nanomaterials (Basel, Switzerland) · 2023Article
- Review
- Sustainable-Green Synthesis of Silver Nanoparticles Using AqueousMolecules (Basel, Switzerland) · 2022Article
- Amphotericin B-PEG Conjugates of ZnO Nanoparticles: Enhancement Antifungal Activity with Minimal Toxicity.Pharmaceutics · 2022Article
- Smart nanomaterials for cancer diagnosis and treatment.Nano convergence · 2022Review
- Exploration of nanozymes in viral diagnosis and therapy.Exploration (Beijing, China) · 2022Review
- Double functionalized haemocompatible silver nanoparticles control cell inflammatory homeostasis.PloS one · 2022Article
- Synthesis, Characterization, andFrontiers in bioengineering and biotechnology · 2022Article
- Biofilm-Resistant Nanocoatings Based on ZnO Nanoparticles and Linalool.Nanomaterials (Basel, Switzerland) · 2021Article
- Nanozymes to fight the COVID-19 and future pandemics.Environmental chemistry letters · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The successful integration of nanoparticles into biomedical applications requires modulation of their surface properties so that the interaction with biological systems is regulated to minimize toxicity for biological function. In the present work, we have engineered bioactive surfaces on gold (Au) and silver (Ag) nanoparticles and subsequently evaluated their interaction with mouse skin fibroblasts and macrophages. The Au and Ag nanoparticles were synthesized using tyrosine, tryptophan, isonicotinylhydrazide, epigallocatechin gallate, and curcumin as reducing and stabilizing agents. The nanoparticles thus prepared showed surface corona and exhibited free radical scavenging and enzyme activities with limited cytotoxicity and genotoxicity. We have thus developed avenues for engineering the surface of nanoparticles for biological applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.